AU2023317860A1 - Intranasal administration of bdnf for the treatment of sensorineural hearing loss - Google Patents

Intranasal administration of bdnf for the treatment of sensorineural hearing loss Download PDF

Info

Publication number
AU2023317860A1
AU2023317860A1 AU2023317860A AU2023317860A AU2023317860A1 AU 2023317860 A1 AU2023317860 A1 AU 2023317860A1 AU 2023317860 A AU2023317860 A AU 2023317860A AU 2023317860 A AU2023317860 A AU 2023317860A AU 2023317860 A1 AU2023317860 A1 AU 2023317860A1
Authority
AU
Australia
Prior art keywords
bdnf
treatment
hearing loss
concentration
sensorineural hearing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023317860A
Other languages
English (en)
Inventor
Marcello Allegretti
Lucia Apparente
Andrea Aramini
Laura Brandolini
Franca Cattani
Pasquale COCCHIARO
Nicola DETTA
Anna Rita FETONI
Flavio MANTELLI
Simone MATTIOLI
Tiziana ROMEO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of AU2023317860A1 publication Critical patent/AU2023317860A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2023317860A 2022-08-05 2023-08-04 Intranasal administration of bdnf for the treatment of sensorineural hearing loss Pending AU2023317860A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22189067.6 2022-08-05
EP22189067.6A EP4316462A1 (en) 2022-08-05 2022-08-05 Intranasal administration of bdnf for the treatment of sensorineural hearing loss
PCT/EP2023/071676 WO2024028483A1 (en) 2022-08-05 2023-08-04 Intranasal administration of bdnf for the treatment of sensorineural hearing loss

Publications (1)

Publication Number Publication Date
AU2023317860A1 true AU2023317860A1 (en) 2025-02-13

Family

ID=83080998

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023317860A Pending AU2023317860A1 (en) 2022-08-05 2023-08-04 Intranasal administration of bdnf for the treatment of sensorineural hearing loss

Country Status (8)

Country Link
US (1) US20260048006A1 (https=)
EP (2) EP4316462A1 (https=)
JP (1) JP2025525990A (https=)
CN (1) CN119816318A (https=)
AU (1) AU2023317860A1 (https=)
CA (1) CA3263977A1 (https=)
IL (1) IL318653A (https=)
WO (1) WO2024028483A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4623926A1 (en) * 2024-03-26 2025-10-01 Dompe' Farmaceutici SpA Intranasal administration of bdnf for treatment of primary headaches

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2278999B1 (en) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
WO2019140012A1 (en) * 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
WO2021030452A1 (en) * 2019-08-14 2021-02-18 Decibel Therapeutics, Inc. Permeation enhancers, compositions containing them, and methods of using the same
WO2021151013A1 (en) * 2020-01-24 2021-07-29 Otonomy, Inc. Growth factor formulation for condition associated with otic event
US20240066099A1 (en) * 2020-12-15 2024-02-29 Dompé Farmaceutici S.P.A. Bdnf otic formulations and use thereof

Also Published As

Publication number Publication date
WO2024028483A1 (en) 2024-02-08
EP4565254A1 (en) 2025-06-11
US20260048006A1 (en) 2026-02-19
EP4316462A1 (en) 2024-02-07
CN119816318A (zh) 2025-04-11
CA3263977A1 (en) 2024-02-08
JP2025525990A (ja) 2025-08-07
IL318653A (en) 2025-03-01

Similar Documents

Publication Publication Date Title
McGuinness et al. Exogenous BDNF rescues rat spiral ganglion neurons in vivo
Magnusson et al. Delayed onset of ototoxic effects of gentamicin in treatment of Meniere's disease: rationale for extremely low dose therapy
Noushi et al. Delivery of neurotrophin-3 to the cochlea using alginate beads
US20100254907A1 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
MXPA06011078A (es) Uso de un antagonista del receptor nmda para el tratamiento de tinito inducido por excitotoxicidad coclear.
Kuthubutheen et al. The role of extended preoperative steroids in hearing preservation cochlear implantation
US10966940B2 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20260048006A1 (en) Intranasal administration of bdnf for the treatment of sensorineural hearing loss
WO2024028487A1 (en) Intranasal administration of ngf for the treatment of sensorineural hearing loss
Ryugo et al. Synaptic plasticity after chemical deafening and electrical stimulation of the auditory nerve in cats
CN106852121B (zh) 用于治疗神经感觉性听觉丧失的甾醇衍生物以及相应的组合物
Foecking et al. Testosterone treatment restores vestibular function by enhancing neuronal survival in an experimental closed-head repetitive mild traumatic brain injury model
CN108310386A (zh) mTOR信号通路抑制剂在制备预防或治疗非遗传性听力障碍药物中的用途
Chi et al. Therapeutic efficacy of topical application of dexamethasone to the round window niche after acoustic trauma caused by intensive impulse noise in guinea pigs
Lee et al. Effect of ototoxic drug administration to the endolymphatic sac
US7390482B2 (en) Drug for auditory dysfunction
US12390510B2 (en) Methods of treating sensorineural hearing loss using fibroblast growth factor 2 (FGF2)
El Gandy et al. Jacobs Journal of Otolaryngology
Sly et al. The effect of brain-derived neurotrophic factor and neurotrophin-3 on the auditory nerve response to cochlear implant stimulation.
US20110207689A1 (en) The treatment of hearing loss
Edmunds Potential complications associated with steroid use in the middle and inner ear
Cho et al. Morphologic Change and Hearing Recovery After Intratympanic Application of Insulin-Like Growth Factor-1 in Guinea Pig
Banerjee et al. Otology and neuro-otology